| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 16.0 | 20.4 | 18.1 |
| Other income | 0.1 | 0.7 | 0.2 |
| Total income | 16.0 | 21.1 | 18.3 |
| Profit before exceptional items & tax | 0.4 | 1.7 | 1.5 |
| Profit before tax | 0.4 | 1.7 | 1.5 |
| Net profit | 0.3 | 1.2 | 1.0 |
| Operating margin | 2.5% | 8.1% | 8.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -70.00% |
|---|---|
| Net profit, quarter on quarter | -75.00% |
| Revenue, year on year | -11.60% |
| Operating profit, year on year | -75.00% |
| Operating profit, quarter on quarter | -60.00% |
BSE results filing, NSE: MERCURYLAB. Figures extracted from the filing.
Mercury Laboratories Ltd: key numbers
- Share price
- ₹765.00
- Market cap
- ₹91.80 Cr
- Revenue (annual)
- ₹75.94 Cr
- Net profit (annual)
- ₹4.83 Cr
- P/E (TTM)
- 22.1×Sector 47.4×
- Promoter holding
- 73.66%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mercury Laboratories Ltd
All →Mercury Laboratories Management Change
Mercury Laboratories has appointed Mr. Jaydeepsinh Raj as Manager-HR, effective September 03, 2026.
Mercury Laboratories Annual Report
Mercury Laboratories Ltd has submitted its 45th Annual Report and Notice of the 45th AGM for the financial year 2025-26.
Mercury Laboratories Annual General Meeting
Mercury Laboratories has issued the notice for its 45th Annual General Meeting, scheduled for September 28, 2026. The meeting will address dividend declaration and director re-appointments.
Mercury Laboratories Management Change
Mercury Laboratories appointed Sunil Sharma as Head of Injectable Production effective August 21, 2026. Simultaneously, Ms. Seema Salvi resigned from the same position to pursue other opportunities.
Mercury Laboratories Other Announcement
Mercury Laboratories informs shareholders regarding Tax Deduction at Source (TDS) requirements for the FY 2025-26 dividend. This communication outlines necessary compliance and record-updating procedures.
Mercury Laboratories Board Meeting Date
Mercury Laboratories scheduled a board meeting for July 25, 2026. The board will consider and approve unaudited financial results for the June quarter.